← Back to Screener
Polaryx Therapeutics, Inc. Common Stock (PLYX)
Price$2.52
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (4W)-46.80%
VGM Score60.23
Market Capitalization$132.56M
All Metrics
Book Value / Share (Quarterly)$0.05
Indicated Dividend (Annual)$0.00
Price vs S&P 500 (YTD)-101.68%
EPS (TTM)$-0.08
10-Day Avg Trading Volume0.62M
EPS Excl Extra (TTM)$-0.08
EPS (Annual)$-0.64
ROI (Annual)-644.23%
Cash / Share (Quarterly)$0.07
ROA (Last FY)-607.00%
EBITD / Share (TTM)$-0.06
Cash Flow / Share (Annual)$-0.05
P/B Ratio53.28x
P/B Ratio (Quarterly)143.86x
Net Income / Employee (Annual)$-3,372,900
EPS Incl Extra (Annual)$-0.64
Current Ratio (Annual)17.30x
Quick Ratio (Quarterly)3.07x
3-Month Avg Trading Volume1.44M
Revenue / Employee (TTM)$0
52-Week High$48.91
EPS Excl Extra (Annual)$-0.64
Quick Ratio (Annual)15.99x
13-Week Price Return-8.33%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.45x
Enterprise Value$129.48M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.10
3-Month Return Std Dev227.64%
Net Income / Employee (TTM)$-441,600
ROE (Last FY)-644.23%
EPS Basic Excl Extra (Annual)$-0.64
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.08
Revenue / Share (Annual)$0.00
Year-to-Date Return-92.46%
5-Day Price Return5.18%
EPS Normalized (Annual)$-0.64
Month-to-Date Return-19.27%
EBITD / Share (Annual)$-0.64
EPS Basic Excl Extra (TTM)$-0.08
Price vs S&P 500 (13W)-19.00%
Beta-4.37x
Revenue / Share (TTM)$0.00
52-Week Low$2.07
mGradeB
vgmGradeB
Show chart for
Analyst Recommendations
Apr 2026
May 2026
4.14
4.14
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
PLYXPolaryx Therapeutics, Inc. Common Stock | — | — | B | $2.52 |
| LLYEli Lilly & Co. | D | B | B | $1078.78 |
| JNJJohnson & Johnson | C | C | C | $223.24 |
| ABBVABBVIE INC. | D | C | C | $217.13 |
| MRKMerck & Co., Inc. | C | C | C | $114.70 |
| AZNAstraZeneca PLC | D | B | C | $176.28 |
| NVSNovartis AG | C | C | C | $143.66 |
| NVONovo-Nordisk A/S | B | B | B | $42.00 |
| ABTAbbott Laboratories | C | C | D | $86.99 |
| PFEPfizer Inc. | B | C | C | $25.34 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $32.83 |
About
Polaryx Therapeutics is a clinical-stage biotech company developing oral small molecule therapies for rare pediatric lysosomal storage diseases (LSDs). Its pipeline includes PLX-200, PLX-300, and PLX-100, designed to address the underlying pathophysiology of these genetic disorders. The company focuses on disease-modifying treatments that target core mechanisms common to multiple LSDs.